SAN DIEGO, Nov. 1, 2021 /PRNewswire/
-- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision
oncology company targeting virus-associated malignancies,
today announced that company management is scheduled to
present and host one-on-one meetings at the following upcoming
investor conferences:
Credit
Suisse 30th Annual Healthcare
Conference (virtual)
|
Conference
Dates:
|
November 8 – 12,
2021
|
Presentation
Date:
|
November 11,
2021
|
Presentation
Time:
|
1:50 PM ET
|
Format:
|
Corporate
presentation
|
Jefferies London
Healthcare Conference (in-person)
|
Conference
Dates:
|
November 16 – 17,
2021
|
Presentation
Date:
|
November 17,
2021
|
Presentation
Time:
|
10:40 AM GMT/ 5:40 AM
ET
|
Format:
|
Corporate
presentation
|
Piper Sandler
33rd Annual Healthcare Conference
(virtual)
|
Conference
Dates:
|
November 29 –
December 2, 2021
|
Presentation
Available:
|
November 22, 2021, at
10:00 AM ET
|
Format:
|
Corporate
presentation
|
Evercore ISI
4th Annual HealthCONx Conference
(virtual)
|
Conference
Dates:
|
November 29 –
December 2, 2021
|
Presentation
Date:
|
December 2,
2021
|
Presentation
Time:
|
3:55 PM ET
|
Format:
|
Fireside
chat
|
A live webcast of each of the presentations will be available
under "Events and Webcasts" in the Investors section of the Viracta
website at https://viracta.investorroom.com/events-and-webcasts.
Replays of each webcast will be archived on the Viracta
website for at least 30 days following the presentation.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting
virus-associated malignancies. Viracta's proprietary
investigational drug, nanatinostat, is currently being evaluated in
combination with the antiviral agent valganciclovir as an oral
combination therapy in two Phase 2 clinical trials for EBV-positive
(EBV+) lymphoma and one Phase 1b/2 trial in patients with
EBV+ nasopharyngeal carcinoma and other
EBV+ solid tumors. Viracta is also pursuing the
application of its inducible synthetic lethality approach in other
virus-related cancers. For additional information please
visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations and Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-upcoming-investor-conferences-301413256.html
SOURCE Viracta